These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 35787197)

  • 1. Impact of itch and skin pain on quality of life in adult patients with atopic dermatitis in Japan: results from a real-world, point-in-time, survey of physicians and patients.
    Torisu-Itakura H; Anderson P; Piercy J; Pike J; Sakamoto A; Kabashima K
    Curr Med Res Opin; 2022 Aug; 38(8):1401-1410. PubMed ID: 35787197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2).
    Simpson EL; Prajapati VH; Leshem YA; Chovatiya R; de Bruin-Weller MS; Ständer S; Pink AE; Calimlim BM; Lee WJ; Teixeira H; Ladizinski B; Hu X; Yang Y; Liu Y; Liu M; Grada A; Platt AM; Silverberg JI
    Dermatol Ther (Heidelb); 2024 May; 14(5):1127-1144. PubMed ID: 38696027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2.
    Yosipovitch G; Gooderham MJ; Ständer S; Fonacier L; Szepietowski JC; Deleuran M; Girolomoni G; Su JC; Bushmakin AG; Cappelleri JC; Feeney C; Chan G; Thorpe AJ; Valdez H; Biswas P; Rojo R; DiBonaventura M; Myers DE
    Am J Clin Dermatol; 2024 Jan; 25(1):127-138. PubMed ID: 37624488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attentiveness and mental health in adolescents with moderate-to-severe atopic dermatitis without ADHD.
    Paller AS; Gonzalez ME; Barnum S; Jaeger J; Shao L; Ozturk ZE; Korotzer A
    Arch Dermatol Res; 2024 Jul; 316(8):497. PubMed ID: 39080094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis.
    Silverberg JI; DeLozier A; Sun L; Thyssen JP; Kim B; Yosipovitch G; Nunes FP; Gugiu PC; Doll HA; Eichenfield LF
    Health Qual Life Outcomes; 2021 Oct; 19(1):247. PubMed ID: 34688290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study.
    Kimball AB; Delevry D; Yang M; Chuang CC; Wang Z; Bégo-Le-Bagousse G; Martins B; Wu E; Shumel B; Wang J; Sierka D; Chao J; Strober B
    Dermatol Ther (Heidelb); 2023 Sep; 13(9):2107-2120. PubMed ID: 37552431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitis.
    Wei W; Anderson P; Gadkari A; Blackburn S; Moon R; Piercy J; Shinde S; Gomez J; Ghorayeb E
    J Dermatol; 2018 Feb; 45(2):150-157. PubMed ID: 29131384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated with Improved Quality of Life Outcomes in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis.
    Thyssen JP; Bewley A; Ständer S; Castro C; Misery L; Kim BS; Biswas P; Chan G; Myers DE; Watkins M; Alderfer J; Güler E; Silverberg JI
    Dermatology; 2024; 240(2):243-253. PubMed ID: 38081155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis.
    Simpson EL; Guttman-Yassky E; Margolis DJ; Feldman SR; Qureshi A; Hata T; Mastey V; Wei W; Eckert L; Chao J; Arnold RJG; Yu T; Vekeman F; Suárez-Fariñas M; Gadkari A
    JAMA Dermatol; 2018 Aug; 154(8):903-912. PubMed ID: 29971354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvements in itch and sleep following treatment with baricitinib in combination with topical corticosteroids are associated with better quality of life and productivity in adult patients with moderate-to-severe atopic dermatitis: a post hoc analysis from BREEZE-AD7.
    Masuda K; Delozier AM; Kolodsick J; Buchanan A; Pink AE; Sun L; Wang Z; Stingeni L; Thac I D
    Eur J Dermatol; 2022 Apr; 32(2):237-243. PubMed ID: 35866910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inadequate Disease Control, Treatment Dissatisfaction, and Quality-of-Life Impairments Among US Patients Receiving Topical Therapy for Atopic Dermatitis.
    Anderson P; Austin J; Lofland JH; Piercy J; Joish VN
    Dermatol Ther (Heidelb); 2021 Oct; 11(5):1571-1585. PubMed ID: 34268709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Burden of skin pain in atopic dermatitis.
    Vakharia PP; Chopra R; Sacotte R; Patel KR; Singam V; Patel N; Immaneni S; White T; Kantor R; Hsu DY; Silverberg JI
    Ann Allergy Asthma Immunol; 2017 Dec; 119(6):548-552.e3. PubMed ID: 29223299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement in sleep and itch and enhanced quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a phase 3 trial of baricitinib therapy.
    Lio PA; Simpson EL; Han G; Soung J; Ball S; Sun L; Casillas M; DeLozier AM; Ding Y; Eichenfield LF
    J Dermatolog Treat; 2022 Jun; 33(4):2057-2062. PubMed ID: 34176407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes.
    Silverberg JI; Thyssen JP; Simpson EL; Yosipovitch G; Ständer S; Valdez H; Rojo R; Biswas P; Myers DE; Feeney C; DiBonaventura M
    Am J Clin Dermatol; 2021 Jul; 22(4):541-554. PubMed ID: 33954933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the burden of pruritus due to atopic dermatitis in Japan by patient-reported outcomes.
    Murota H; Koike Y; Ishii K; Calimlim BM; Ludwikowska M; Toumi M; Kawaguchi I
    J Med Econ; 2021; 24(1):1280-1289. PubMed ID: 34816787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal course of cognitive impairment in patients with atopic dermatitis.
    Jackson-Cowan L; Silverberg JI
    Arch Dermatol Res; 2023 Aug; 315(6):1553-1560. PubMed ID: 36708375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Patient and Physician Disconnect on Satisfaction with Treatment for Atopic Dermatitis in Japan.
    Wang C; Aranishi T; Reed C; Anderson P; Austin J; Davis VA; Quinones E; Piercy J
    Dermatol Ther (Heidelb); 2023 Feb; 13(2):505-522. PubMed ID: 36515820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16.
    Thyssen JP; de Bruin-Weller M; Costanzo A; Grond S; Schuster C; Liu C; Rueda MJ; Chen YF; Pinter A; Bieber T
    Adv Ther; 2023 Aug; 40(8):3574-3587. PubMed ID: 37332021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials.
    Reich K; DeLozier AM; Nunes FP; Thyssen JP; Eichenfield LF; Wollenberg A; Ross Terres JA; Watts SD; Chen YF; Simpson EL; Silverberg JI
    J Dermatolog Treat; 2022 May; 33(3):1521-1530. PubMed ID: 33222559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Symptom burden of patients with moderate-to-severe atopic dermatitis.
    Egeberg A; Anderson P; Piercy J; Massey L; Cappelleri JC; Encinas GA; Feeney C; Dibonaventura M
    Eur J Dermatol; 2021 Dec; 31(6):752-758. PubMed ID: 34935621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.